✦ LIBER ✦

Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon

✍ Scribed by Joan Camps; Nicolás García; José I. Riezu-Boj; María P. Civeira; Jesús Prieto

Book ID: 118566405
Publisher: Elsevier Science
Year: 1993
Tongue: English
Weight: 397 KB
Volume: 19
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(05)80550-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Diffuse cutaneous eruption due to interf

Diffuse cutaneous eruption due to interferon alfa and ribavirin treatment of chronic hepatitis C

✍ E Avk; G Uslu; AÖ Karaoğlu; N Şendur; G Karaman 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 561 KB

Interferon alfa-2b (IFN-A2B)/ribavirin c

Interferon alfa-2b (IFN-A2B)/ribavirin compared to consensus interferon (CIFN)/ribavirin in treatment of chronic hepatitis C

✍ M.H. Sjogren; K. Holtzmuller; R.W. Sjogren 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Combination therapy with interferon plus

Combination therapy with interferon plus ribavirin in patients with mixed cryoglobulinaemia associated to HCV chronic hepatitis unresponsive to ALFA interferon

✍ C. Donada; A. Crucitti; G. Zanette; S. Piva; L. Tommasi; C. Mazzaro; V. Donadon 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 173 KB

Long-term efficacy of ribavirin plus int

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C

✍ MY Lai; JH Kao; PM Yang; JT Wang; PJ Chen; KW Chan; JS Chu; DS Chen 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 300 KB

Interferon alfa plus ribavirin in chroni

Interferon alfa plus ribavirin in chronic hepatitis C relapsers and non-responders to previous interferon alfa course

✍ J. Salmerón; R. Martín Vivaldi; M. De la Mata; M. Romero; J. Perez Moreno; J. Ag 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Cost-effectiveness of interferon alfa 2b

Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C

✍ W. Ray Kim; John J. Poterucha 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 34 KB 👁 2 views

In their paper in the November issue of HEPATOLOGY, Younossi et al. 1 may have overestimated the cost effectiveness of interferon-ribavirin treatment. This mainly stems from their failure to take into account the fact that patients who achieve sustained response are not homogenous with respect to th